Browse > Home / Actoplus / Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

October 21, 2009

New given conditions steady patient treatment satisfaction from the LEAD(TM) 6 experimental knowledge presented adhering the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do through exenatide.(1)

To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/prne/novo/37559/

Specifically, among the 379 patients who completed the Diabetes Treatment Satisfaction Questionnaires (DTSQ) during the LEAD(TM) 6 sorrow, those taking liraglutide perceived less hypoglycaemia (abnormally low blood sugar levels) or hyperglycaemia (abnormally high courage compliment levels) compared to those on exenatide.

"Liraglutide has shown here in a convincing study that it is associated with less nausea, smaller perceived hypoglycaemia and definitely higher calm comfort compared to exenatide," said Dr Wolfgang Schmidt, professor and chair of the Department of Medicine at St. Josef-Hospital and one of the principal investigators in the experiment.

"Patient-reported outcomes data is an important extension of the efficacy data. If a long-suffering is satisfied by his or her treatment, then they are much more well-adapted to really stick to the management over the long term, which is that cannot be spared in model 2 diabetes," Dr Schmidt noted.

Treatment satisfaction was also evaluated during an open-label dilation of the LEAD(TM) 6 trial, in what one. patients were either switched from exenatide to liraglutide or continued onward liraglutide for not the same 14 weeks. These results show that switching patients from exenatide to liraglutide further improves enduring satisfaction, as evidenced by the larger rise in DTSQs scores for switched patients compared to those who continued upon the body liraglutide from weeks 26-40.

Other lock opener liraglutide data at IDF Congress

Two withdrawn meta-analyses of all six LEAD(TM) (Liraglutide Effect and Action in Diabetes) trials were likewise presented at the meeting. Meta-analyses are a type of statistical analysis that summarise the results on the side of a given method of treating from several different studies in order to evaluate its overall effect on a characteristic outcome.

The meta-analyses presented at the meeting documented:

1) Liraglutide’session substantial effect on lipid profile in patients with form 2 diabetes(2) and 2) liraglutide’s ability to subside one as well during the time that the other HbA1C and weight without inducing hypoglycaemia versus that of the other active comparators in the LEAD(TM) programme including exenatide, glimepiride, rosiglitazone and insulin glargine.(3) Each of the meta-analyses comprised 3,967 people with impressed sign 2 diabetes.

In the lipid meta-analysis, sum cholesterol, unhandsome density lipoprotein, free fatty acids and triglycerides were quite statistically significantly reduced from baseline with liraglutide extremely 26 weeks of treatment. Furthermore, gross cholesterol and low density lipoproteins were significantly reduced through liraglutide manipulation compared to rosiglitazone, glimepiride or insulin glargine.

In the meta-analysis evaluating effectiveness on combined treatment targets of HbA1c and consequence without hypoglycaemia, greater quantity patients in the liraglutide group reached HbA1c(less than)7.0% with no weight gain or hypoglycaemia than those on comparator treatments. Patients were more likely to reach these treatment goals without hypoglycaemia on liraglutide compared to other commonly used diabetes treatments.

LEAD(TM) 6 trial, extension and sub-analysis designs

LEAD(TM) 6 was a 26-week, open-label trial of 464 patients with type 2 diabetes and HbA1c levels between 7-11%, who were randomised to once-daily liraglutide or twice-daily exenatide on a metformin more or minus sulphonylurea therapy background. Results from this direct comparison trial were published in The Lancet.

In the LEAD(TM) 6 extension testing, patients were one and the other switched from exenatide to liraglutide or continued on liraglutide for a period of 14 weeks. All 389 patients who completed the randomised trial entered into the extendedness phase.

In the patient-reported outcomes analysis, a subgroup of 379 patients had treatment satisfaction evaluated using sum of two units versions of the Diabetes Treatment Satisfaction Questionnaire: status (DTSQs) at baseline and week 26, and change (DTSQc) at week 26. Patients had higher overall treatment satisfaction with liraglutide than they did with exenatide and, in particular, their perception of hyperglycaemia and hypoglycaemia was reduced more by dint of. liraglutide than by exenatide.

In the 14-week extendedness, 313 patients answered the DTSQs at weeks 34 and 40 and the DTSQc at week 34. These results showed that switching patients from exenatide to liraglutide further improves patient satisfaction, as evidenced by the larger go in treatment reparation scores towards switched patients compared to those who continued in succession liraglutide from weeks 26-40.

Source: NOVO NORDISK

Written by Samanta · Filed Under Actoplus